1 not yet recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Refractory AML: new trials by email Literature Review of Refractory AML trials Research Report on Refractory AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
Leukemia (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Acute (1)
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Cyclophosphamide (1) · Whole-Body Irradiation (1) · fludarabine (1)